Core Insights - Ocean Power Technologies, Inc. has secured a contract for a fully integrated WAM-V from a new Nordic underwater research customer, marking an expansion into the Nordics region [1] - The contract reflects ongoing demand across multiple sectors, including defense, security, and autonomous underwater surveys, indicating a positive market trend for the company's systems [2] Company Overview - Ocean Power Technologies provides intelligent maritime solutions and services aimed at enhancing safety, cleanliness, and productivity in ocean operations across various markets, including defense, oil and gas, science and research, and offshore wind [3] - The company offers products such as Merrows™ for Maritime Domain Awareness and PowerBuoy® platforms for clean electric power and data communications, along with WAM-V® autonomous surface vessels [3]

Core Viewpoint - Cyabra, Inc. has successfully completed its business combination with Trailblazer Merger Corporation I, and its common stock is set to begin trading on Nasdaq under the ticker symbol "CYAB" on March 27, 2026 [1][2]. Company Overview - Cyabra, formerly known as Trailblazer Holdings, Inc., focuses on identifying coordinated manipulation in online narratives to help organizations protect trust and authenticity [1][5]. - The company aims to restore trust for global enterprises and governments by analyzing actors, behaviors, and content, translating evidence into actionable steps [5]. Management and Operations - The combined entity will continue under Cyabra's existing management team, led by Co-Founder and CEO Dan Brahmy [2]. - Cyabra positions itself as the first publicly traded company dedicated exclusively to combating disinformation, providing a platform for governments and enterprises to restore trust and expose inauthentic actors [3]. Business Combination Details - The business combination was approved by Trailblazer's stockholders on February 18, 2026, marking a significant step in Cyabra's mission to defend digital reality [2][3]. - Following the merger, Trailblazer's common stock and rights will no longer be listed on Nasdaq [2]. Advisory Information - Legal advisors for Cyabra included Lowenstein Sandler LLP and Goldfarb Gross Seligman, while LifeSci Capital served as the financial advisor [4]. - Trailblazer Merger Corporation I was advised by Loeb & Loeb LLP and Sullivan & Worcester LLP [4].

Core Insights - Quantum BioPharma Ltd. has reported strong financial improvements, including a significant cash position and reduced liabilities, indicating a solid operational foundation for future growth [2][3][10] Financial Performance - As of the date of filing, the company has $11.3 million USD in cash and digital assets, providing a cash runway through January 2028 [2][12] - Operating expenses for the year ended December 31, 2025, decreased to $15.3 million USD from $16.1 million USD in 2024, reflecting a 5% improvement [3] - Trade and other payables were reduced by approximately 50%, from $4.1 million USD to $2.0 million USD, showcasing improved working capital management [3] Research and Development - External research and development fees decreased to $2.8 million USD in 2025 from $6.1 million USD in 2024, attributed to the completion of Phase 1 clinical trials and R&D tax credits from the Australian government [4] - The company is advancing its multiple sclerosis drug candidate, Lucid-21-302, with completed Phase 1 toxicity studies showing no significant side effects [11][13] Corporate Developments - The results of the dietary supplement unbuzzd were published in a peer-reviewed journal, demonstrating its effectiveness in reducing blood alcohol concentration and hangover symptoms [5] - Quantum has received a Product License from Health Canada for its natural health product Qlarity, allowing sales in Canada [5][13] - Unbuzzd has initiated a Regulation D 506(c) offering to raise up to $5.0 million USD for growth and distribution [5] Legal Matters - The company is involved in a lawsuit against CIBC and RBC regarding alleged stock market manipulation, with ongoing court proceedings [7][8] Management Commentary - Management expressed confidence in the company's strengthened cash position and operational efficiencies, aiming for continued growth and development of its product pipeline [10][13]

Group 1 - The Company, Inflection Point Acquisition Corp. VI, has priced its initial public offering (IPO) at $10.00 per unit, with a total of 22,000,000 units being offered [1] - The units will be listed on Nasdaq under the ticker symbol "IPFXU" starting March 27, 2026, and each unit consists of one Class A ordinary share and one-third of a redeemable warrant [1] - The offering is expected to close on March 30, 2026, subject to customary closing conditions, with Cantor Fitzgerald & Co. as the book-running manager [3] Group 2 - The Company aims to pursue a business combination with a North American or European business in disruptive growth sectors, leveraging the expertise of its management team [2][7] - The management team includes CEO Kevin Shannon, CFO Adam Saks, and Chairman Michael Blitzer, among others [2] Group 3 - The Company has granted underwriters a 45-day option to purchase up to an additional 3,300,000 units to cover over-allotments [3] - A registration statement related to the securities was declared effective by the SEC on March 26, 2026 [4]

Core Insights - TMC the metals company Inc. reported a transformative year in 2025, focusing on a clear U.S. permitting pathway and strong policy support, ending the year with $162 million in liquidity [4][18] - The company is negotiating for a nodule processing and refining hub in Brownsville, Texas, with plans for a 12 million tonnes per annum facility [2][10] - TMC has established a strategic partnership with Mariana Minerals to develop AI-enabled process controls for the nodule processing facility [3][11] Financial Highlights - As of December 31, 2025, TMC held approximately $117.6 million in cash, with a net loss of $40.4 million for Q4 2025, compared to a net loss of $16.1 million in Q4 2024 [8][19] - For the full year 2025, the company reported a net loss of $319.8 million, or $0.83 per share, compared to a net loss of $81.9 million, or $0.25 per share in 2024 [21] - General and administrative expenses increased to $99.8 million in 2025 from $30.6 million in 2024, primarily due to increased share-based compensation [20][21] Operational Developments - TMC holds an exclusive negotiation right for a 1,466-acre site at the Port of Brownsville for developing a domestic nodule processing and refining ecosystem [10] - The company is exploring capital-light, tolled processing options and progressing prerequisites for U.S. government support for the processing hub [7][9] - NOAA has determined that TMC USA's consolidated deep-seabed mining application is in substantial compliance, marking a significant step in the regulatory process [13][16] Strategic Partnerships - TMC signed a Strategic Partnership Agreement with Mariana Minerals to focus on the feasibility study for the nodule processing facility in Brownsville [11][12] - The partnership aims to leverage Mariana's AI-driven approach to expedite project execution and enhance operational efficiency [11][12] Industry Context - The U.S. and Japan have agreed on a critical minerals action plan to strengthen supply chain resilience, which includes accelerating research into commercially viable deep-sea mining [17] - TMC remains the only company to have demonstrated commercial viability through SEC-compliant mineral reserves, positioning itself as a leader in the offshore mining sector [17]

Core Viewpoint - Luckin Coffee Inc. has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission [1][2] Group 1: Financial Reporting - The 2025 Annual Report includes Luckin Coffee's audited consolidated financial statements prepared under U.S. GAAP [2] Group 2: Company Overview - Luckin Coffee has established a technology-driven retail network aimed at providing high-quality, convenient, and affordable coffee products [4] - Founded in 2017 and based in China, Luckin Coffee aims to build a world-class coffee brand and integrate into daily life [4]

Company Announcement - The Annual General Meeting (AGM) of Royal Unibrew A/S is scheduled for April 29, 2026, at 4 pm (CEST) [1] - The AGM will be conducted as a fully electronic meeting [1] - Additional documents and information regarding the AGM can be accessed on the company's investor relations website [1] Contact Information - For further inquiries, contact Flemming Ole Nielsen, Head of Investor Relations, via email or telephone [1]

Core Viewpoint - Hydrofarm Holdings Group, Inc. reported a significant decline in net sales and an increase in net loss for the fourth quarter of 2025, primarily due to industry oversupply and restructuring efforts aimed at improving profitability and financial stability [4][5][8]. Financial Performance - Net sales for Q4 2025 decreased by 32.7% to $25.1 million from $37.3 million in the prior year, driven by a 27.3% decline in volume/mix and a 5.6% decrease in price [5]. - Gross profit increased to $2.1 million (8.5% of net sales) compared to $1.8 million (4.9% of net sales) in the prior year, with adjusted gross profit rising to $3.9 million (15.4% of net sales) from $3.6 million (9.6% of net sales) [6]. - Selling, general and administrative (SG&A) expenses were reduced to $9.6 million from $17.0 million, with adjusted SG&A expenses decreasing to $8.8 million from $10.8 million [7]. - The net loss for Q4 2025 was $242.2 million, significantly higher than the $17.5 million loss in the prior year, primarily due to a $232.2 million impairment charge related to intangible assets [8]. - Adjusted EBITDA improved to $(4.9) million from $(7.3) million in the prior year, reflecting higher adjusted gross profit and lower adjusted SG&A expenses [9]. Balance Sheet and Cash Flow - As of December 31, 2025, the company had $6.3 million in cash and a principal balance of $114.4 million on its Term Loan [10]. - Cash used in operating activities was $(4.0) million, with free cash flow reported at $(4.3) million, reflecting lower earnings and working capital changes [11]. - The company deferred a $2.8 million interest payment on its Term Loan, resulting in an event of default and subsequent reclassification of the Term Loan to current liabilities [12]. Strategic Initiatives - The company is focused on driving high-quality revenue streams, improving profit margins, and strengthening its financial position through cost reductions and operational changes [13]. - Significant progress has been made in consolidating U.S. manufacturing facilities and reducing distribution centers to enhance efficiency [4].

Core Viewpoint - Next Technology Holding Inc. has successfully closed a registered direct offering, raising approximately $157 million through the sale of common stock and pre-funded warrants [2][3]. Group 1: Offering Details - The offering consisted of 71,381,818 shares of common stock priced at $1.10 per share and pre-funded warrants priced at $1.099 each [1]. - The transaction was finalized on March 26, 2026, and the gross proceeds amounted to around $157 million [2]. Group 2: Regulatory Information - The offering was conducted under a shelf registration statement on Form S-3, which became effective on November 20, 2025 [3]. - A final prospectus supplement detailing the offering terms was filed with the SEC on March 25, 2026 [3]. Group 3: Company Overview - Next Technology Holding Inc. is a technology company established in Wyoming, focusing on a dual-engine strategy of "AI plus digital assets" [5]. - The company provides AI-enabled SaaS software solutions to industrial clients across the Asia-Pacific region and holds digital assets, including Bitcoin, which may be leveraged for financing or income generation [5].

Core Viewpoint - Incannex Healthcare Inc. has reactivated its share repurchase program, indicating that the current market valuation does not reflect the company's financial strength and clinical progress [2][4][5]. Financial Position - The company has approximately $75 million in cash and no debt, providing significant financial flexibility to advance its clinical pipeline [3][6]. - As of December 31, 2025, approximately $18.5 million remains available for repurchases under the share repurchase program [7]. Clinical Development - Incannex is advancing clinical-stage product candidates, including IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder, which are expected to unlock meaningful value [3][6][9]. - The company focuses on developing combination medicines targeting chronic conditions with limited treatment options [9]. Buyback Program Strategy - The share buyback program will be utilized opportunistically, considering market conditions and the company's broader capital requirements [7][8]. - The program does not obligate the company to acquire a specific number of shares and may be modified or suspended at the company's discretion [8].